Skip to main content

Table 1 Key efficacy outcomes by independent subgroups at screening analyzed at week 16

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Endpoints, % responders (n/M) Subgroups Pooled secukinumab 150 mg Placebo
ASAS40 CRP+ 44.5§ (94/211) 26.7 (28/105)
CRP− 34.8 (55/158) 29.6 (24/81)
MRI+ 42.9§ (114/266) 27.3 (38/139)
MRI− 34.0 (35/103) 29.8 (14/47)
HLA-B27+ 43.9 (111/253) 32.6 (42/129)
HLA-B27− 32.7 (37/113) 16.4 (9/55)
Male 51.2§ (84/164) 30.8 (28/91)
Female 31.7 (65/205) 25.3 (24/95)
BASDAI50 CRP+ 40.3* (85/211) 19.0 (20/105)
CRP− 33.5 (53/158) 23.5 (19/81)
MRI+ 38.7* (103/266) 19.4 (27/139)
MRI− 34.0 (35/103) 25.5 (12/47)
HLA-B27+ 41.5 (105/253) 24.8 (32/129)
HLA-B27− 29.2§ (33/113) 10.9 (6/55)
Male 45.1§ (74/164) 26.4 (24/91)
Female 31.2§ (64/205) 15.8 (15/95)
ASAS PR CRP+ 23.7* (50/211) 6.7 (7/105)
CRP− 18.4§ (29/158) 7.4 (6/81)
MRI+ 21.4* (57/266) 6.5 (9/139)
MRI− 21.4 (22/103) 8.5 (4/47)
HLA-B27+ 25.3* (64/253) 8.5 (11/129)
HLA-B27− 13.3 (15/113) 3.6 (2/55)
Male 28.7* (47/164) 9.9 (9/91)
Female 15.6 (32/205) 4.2 (4/95)
ASDAS-CRP ID CRP+ 20.9* (44/211) 3.8 (4/105)
CRP− 21.5 (34/158) 13.6 (11/81)
MRI+ 23.7* (63/266) 8.6 (12/139)
MRI− 14.6 (15/103) 6.4 (3/47)
HLA-B27+ 24.5* (62/253) 9.3 (12/129)
HLA-B27− 14.2 (16/113) 5.5 (3/55)
Male 29.9* (49/164) 9.9 (9/91)
Female 14.1 (29/205) 6.3 (6/95)
  1. NRI data presented for all variables
  2. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CRP C-reactive protein, HLA human leukocyte antigen, ID inactive disease, M number of evaluable patients, MRI magnetic resonance imaging, NRI non-responder imputation, PR partial remission
  3. *P < 0.0001, P < 0.001, §P < 0.01, P < 0.05 versus placebo